Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
Reversible MAOB Inhibitor | Small molecule | Neurological disease | Parkinson's disease | Phase I | Global |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
MAB-H5547 | Human | Human MAOB / Monoamine Oxidase B Protein, His Tag (active enzyme) | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Rasagiline Mesylate | Lu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012 | Approved | Teva | Azilect, Agilect | EU | Parkinson Disease | Teva Bv | 2005-02-21 | Supranuclear Palsy, Progressive; Restless Legs Syndrome; Parkinson Disease; Synucleinopathies; Alzheimer Disease; Dementia; REM Sleep Behavior Disorder; Multiple System Atrophy | Details |
Selegiline | Approved | Mylan Nv, Somerset Inc | Emsam | United States | Depressive Disorder, Major | Somerset Pharmaceuticals Inc | 2006-02-27 | Tobacco Use Cessation; Depressive Disorder, Major; Tobacco Use Disorder; Amphetamine-Related Disorders; Cocaine-Related Disorders | Details | |
Selegiline Hydrochloride | FPF-1100; E-250 (free base) | Approved | Sanofi | FP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegiline | Mainland China | Parkinson Disease | Chinoin Pharmaceutical And Chemical Works Co Ltd | 1989-06-05 | HIV Infections; Marijuana Abuse; Parkinson Disease; Cognition Disorders | Details |
Safinamide Methanesulfonate | PNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125; PNU-151774; FCE-26743 | Approved | Newron Pharmaceutical | Equfina, Xadago | EU | Parkinson Disease | Zambon Spa | 2015-02-23 | Renal Insufficiency; Parkinson Disease; Hepatic Insufficiency; Dyskinesia, Drug-Induced; Multiple System Atrophy | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate | P2B-001 | Phase 3 Clinical | Pharma Two B Ltd | Parkinson Disease | Details |
Vafidemstat | ORY-2001 | Phase 2 Clinical | Oryzon Genomics Sa | Schizophrenia; Alzheimer Disease; Kabuki syndrome; Borderline Personality Disorder | Details |
KDS-2010 | KDS2010; KDS-2010 | Phase 2 Clinical | NeuroBiogen | Alzheimer Disease; Obesity | Details |
Rasagiline transdermal patch (Teikoku Pharma) | Phase 1 Clinical | Teikoku Pharma | Parkinson Disease | Details | |
SKL-PD | YKP-10461; SKL-PD | Phase 1 Clinical | SK Biopharmaceuticals Co Ltd | Parkinson Disease | Details |
Rasagiline Mesylate Transdermal Patch(world leader) | Phase 1 Clinical | Guizhou Shiling Pharmaceutical Co Ltd, Shanghai World Ling Pharmaceutical Co Ltd | Parkinson Disease | Details | |
HEC-122505MsOH | HEC-122505MsOH; HEC-122505-MsOH; HEC122505MsOH | Phase 1 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Parkinson Disease | Details |
PXS-5131 | PXS-5131 | Innovent Biologics(Suzhou) Co Ltd, Syntara Ltd | Details |
This web search service is supported by Google Inc.